Table 2. Antihypertensive medications in patients enrolled in the Global SYMPLICITY Registry-Taiwan.
| Baseline | 6 Months | 12 Months | 24 Months | 36 Months | ||||||
| Symplicity FlexTM (N = 8) | Symplicity SpyralTM (N = 18) | Symplicity FlexTM (N = 8) | Symplicity SpyralTM (N = 17) | Symplicity FlexTM (N = 8) | Symplicity SpyralTM (N = 16) | Symplicity FlexTM (N = 8) | Symplicity SpyralTM (N = 9) | Symplicity FlexTM (N = 8) | Symplicity SpyralTM (N = 0) | |
| Number of antihypertensive medication classes | 4.3 ± 1.3 | 4.8 ± 1.5 | 4.3 ± 1.5 | 4.3 ± 1.5 | 4.4 ± 1.4 | 4.7 ± 1.0 | 4.3 ± 1.5 | 5.0 ± 1.1 | 4.3 ± 1.5 | - |
| ACE inhibitors | 12.5% (1/8) | 5.6% (1/18) | 12.5% (1/8) | 0.0% (0/17) | 25.0% (2/8) | 6.3 % (1/16) | 25.0% (2/8) | 11.1% (1/9) | 25.0% (2/8) | - |
| Angiotensin receptor blockers | 75.0% (6/8) | 83.3% (15/18) | 62.5% (5/8) | 88.2% (15/17) | 75.0% (6/8) | 81.3% (13/16) | 62.5% (5/8) | 55.6% (5/9) | 62.5% (5/8) | - |
| Calcium channel blockers | 62.5% (5/8) | 83.3% (15/18) | 75.0% (6/8) | 76.5% (13/17) | 75.0% (6/8) | 93.8% (15/16) | 62.5% (5/8) | 88.9% (8/9) | 62.5% (5/8) | - |
| Diuretics | 62.5% (5/8) | 77.8% (14/18) | 62.5% (5/8) | 70.6% (12/17) | 62.5% (5/8) | 75.0% (12/16) | 62.5% (5/8) | 77.8% (7/9) | 62.5% (5/8) | - |
| Aldosterone antagonists | 37.5% (3/8) | 38.9% (7/18) | 37.5% (3/8) | 29.4% (5/17) | 37.5% (3/8) | 37.5% (6/16) | 37.5% (3/8) | 55.6% (5/9) | 37.5% (3/8) | - |
| Centrally acting sympatholytics | 0.0% (0/8) | 5.6% (1/18) | 12.5% (1/8) | 5.9% (1/17) | 0.0% (0/8) | 0.0% (0/16) | 0.0% (0/8) | 0.0% (0/9) | 0.0% (0/8) | - |
| Direct renin inhibitor | 0.0% (0/8) | 0.0% (0/18) | 0.0% (0/8) | 0.0% (0/17) | 0.0% (0/8) | 0.0% (0/16) | 0.0% (0/8) | 0.0% (0/9) | 0.0% (0/8) | - |
| β-blockers | 100.0% (8/8) | 72.2% (13/18) | 100.0% (8/8) | 64.7% (11/17) | 100.0% (8/8) | 81.3% (13/16) | 100.0% (8/8) | 88.9% (8/9) | 100.0% (8/8) | - |
| α-adrenergic blocker | 50.0% (4/8) | 77.8% (14/18) | 37.5% (3/8) | 58.8% (10/17) | 37.5% (3/8) | 56.3% (9/16) | 50.0% (4/8) | 66.7% (6/9) | 50.0% (4/8) | - |
| Direct-acting vasodilators | 25.0% (2/8) | 33.3% (6/18) | 25.0% (2/8) | 35.3% (6/17) | 25.0% (2/8) | 37.5% (6/16) | 25.0% (2/8) | 55.6% (5/9) | 25.0% (2/8) | - |
Values are presented as % or mean ± SD. ACE, angiotensin converting enzyme; SD, standard deviation.